FTXH Holdings — First Trust Nasdaq Pharmaceuticals ETF
All 51 reported holdings of First Trust Nasdaq Pharmaceuticals ETF (FTXH) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Eli Lilly & Company | 7.77% | $2.82M |
| Abbvie, Inc. | 7.39% | $2.68M |
| Merck & Company, Inc. | 7.07% | $2.56M |
| Johnson & Johnson | 6.96% | $2.52M |
| Bristol-Myers Squibb Company | 6.29% | $2.28M |
| Biogen, Inc. | 3.84% | $1.39M |
| Viatris, Inc. | 3.62% | $1.31M |
| Cardinal Health, Inc. | 3.53% | $1.28M |
| Vertex Pharmaceuticals, Inc. | 3.41% | $1.23M |
| Amgen, Inc. | 3.18% | $1.15M |
| Pfizer, Inc. | 2.97% | $1.08M |
| Gilead Sciences, Inc. | 2.89% | $1.05M |
| United Therapeutics Corp. | 2.72% | $987.21K |
| Regeneron Pharmaceuticals, Inc. | 2.72% | $984.57K |
| Jazz Pharmaceuticals PLC | 2.49% | $901.47K |
| Incyte Corp. | 2.39% | $866.98K |
| Illumina, Inc. | 1.98% | $718.79K |
| Zoetis, Inc. | 1.87% | $676.71K |
| Exelixis, Inc. | 1.72% | $625.06K |
| Charles River Laboratories International, Inc. | 1.49% | $539.08K |
| Medpace Holdings, Inc. | 1.41% | $511.58K |
| Ptc Therapeutics, Inc. | 1.37% | $496.84K |
| Neurocrine Biosciences, Inc. | 1.37% | $495.32K |
| Alkermes PLC | 1.35% | $490.73K |
| Halozyme Therapeutics, Inc. | 1.21% | $437.76K |
| Biomarin Pharmaceutical, Inc. | 1.11% | $404.03K |
| Twist Bioscience Corp. | 1.03% | $372.32K |
| Spyre Therapeutics, Inc. | 0.97% | $350.50K |
| Travere Therapeutics, Inc. | 0.89% | $323.82K |
| Tg Therapeutics, Inc. | 0.86% | $310.03K |
| Elanco Animal Health, Inc. | 0.83% | $300.49K |
| 10x Genomics, Inc. | 0.78% | $282.45K |
| Guardant Health, Inc. | 0.75% | $271.25K |
| Ligand Pharmaceuticals, Inc. | 0.75% | $270.57K |
| Arcus Biosciences, Inc. | 0.71% | $257.00K |
| Amneal Pharmaceuticals, Inc. | 0.69% | $251.19K |
| Arrowhead Pharmaceuticals, Inc. | 0.66% | $237.85K |
| Catalyst Pharmaceuticals, Inc. | 0.64% | $231.23K |
| Krystal Biotech, Inc. | 0.63% | $228.95K |
| Protagonist Therapeutics, Inc. | 0.62% | $226.04K |
| Moderna, Inc. | 0.61% | $222.00K |
| Mirum Pharmaceuticals, Inc. | 0.59% | $215.41K |
| Kymera Therapeutics, Inc. | 0.59% | $213.17K |
| Roivant Sciences Ltd. | 0.57% | $207.67K |
| Acadia Pharmaceuticals, Inc. | 0.48% | $174.92K |
| Ionis Pharmaceuticals, Inc. | 0.46% | $165.95K |
| Arcutis Biotherapeutics, Inc. | 0.46% | $165.08K |
| Alnylam Pharmaceuticals, Inc. | 0.42% | $153.53K |
| Supernus Pharmaceuticals, Inc. | 0.40% | $144.32K |
| Tarsus Pharmaceuticals, Inc. | 0.39% | $141.55K |
| Dreyfus Government Cash Management Funds | 0.10% | $37.78K |
FTXH overview: performance, fees, allocation and SEC filings